Ontology highlight
ABSTRACT:
SUBMITTER: Szokol B
PROVIDER: S-EPMC4027597 | biostudies-literature | 2014 Apr
REPOSITORIES: biostudies-literature
ACS medicinal chemistry letters 20140130 4
Activating mutations in the epidermal growth factor receptor (EGFR) have been identified in a subset of non-small cell lung cancer (NSCLC), which is one of the leading cancer types worldwide. Application of EGFR tyrosine kinase inhibitors leads to acquired resistance by secondary EGFR mutations or by amplification of the hepatocyte growth factor receptor (c-Met) gene. Although several EGFR and c-Met inhibitors have been reported, potent dual EGFR/c-Met inhibitors, which can overcome this latter ...[more]